NASH With Fibrosis
11
3
5
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
1 terminated out of 11 trials
75.0%
-11.5% vs benchmark
9%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
Non-invasive Tests for Non-alcoholic Steato-hepatitis
Non-alcoholic Steatohepatitis Registry Platform Study
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
Effectiveness of Bariatric Surgery for NAFLD/NASH
AGED Diagnostics Liver Disease Assessment
Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification
Fibrosis Reduction in Non Alcoholic Steatohepatitis